<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Etodolac</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00749</strong>&#160; (APRD00067)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Etodolac is a non-steroidal anti-inflammatory drug (<span class="caps">NSAID</span>) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00749/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00749/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00749.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00749.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00749.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00749.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00749.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00749">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>&#201;todolac</td><td>French</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Etodolac</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>INN, BAN, USAN</td></tr><tr><td>Etodolaco</td><td>Spanish</td><td>INN</td></tr><tr><td>Etodolacum</td><td>Latin</td><td>INN</td></tr><tr><td>Etodolic acid</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IS</td></tr><tr><td>Etodols&#228;ure</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IS</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Bodopine</td><td>Yuan Chou</td></tr><tr><td>Dolarit</td><td>Drogsan</td></tr><tr><td>Dolchis</td><td>Korea United Pharm</td></tr><tr><td>Doloc</td><td>Unifarma</td></tr><tr><td>Dualgan</td><td>ITF</td></tr><tr><td>Eccoxolac</td><td>Meda</td></tr><tr><td>Edolar Fort</td><td>Pfizer</td></tr><tr><td>Edopain</td><td>Incepta</td></tr><tr><td>Edopain ER</td><td>Incepta</td></tr><tr><td>Elac</td><td>Royal</td></tr><tr><td>Elderin</td><td>Lek</td></tr><tr><td>Eric</td><td>U.C. Pharma</td></tr><tr><td>Esodax</td><td>M&#252;nir Sahin</td></tr><tr><td>ETL</td><td>Senton</td></tr><tr><td>Etodin</td><td>Nobel</td></tr><tr><td>Etodin Fort</td><td>Ulkar</td></tr><tr><td>Etodol</td><td>Yuhan</td></tr><tr><td>Etodon</td><td>Shinlon</td></tr><tr><td>Etoflam</td><td>Standard Chem</td></tr><tr><td>Etol Fort</td><td>Nobel</td></tr><tr><td>Etolac</td><td>Alkaloid</td></tr><tr><td>Etomax</td><td>Ipca</td></tr><tr><td>Etomax-ER</td><td>Ipca</td></tr><tr><td>Etonox</td><td>Charoen Bhaesaj</td></tr><tr><td>Etopan</td><td>Winthrop Pharmaceuticals</td></tr><tr><td>Etopin</td><td>U-Liang</td></tr><tr><td>Lodine</td><td>Wyeth</td></tr><tr><td>Lodine XL</td><td>Wyeth</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Etomax-P</td><td>Etodolac and Paracetamol</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anti-inflammatory-agents-non-steroidal">Anti-Inflammatory Agents, Non-Steroidal</a></li>
<li><a href="/mesh/cyclooxygenase-2-inhibitors">Cyclooxygenase 2 Inhibitors</a></li></ul></td></tr><tr><th>CAS number</th><td>41340-25-4</td></tr><tr><th>Weight</th><td>Average: 287.3535<br>Monoisotopic: 287.152143543</td></tr><tr><th>Chemical Formula</th><td>C<sub>17</sub>H<sub>21</sub>NO<sub>3</sub></td></tr><tr><th>InChI Key</th><td>NNYBQONXHNTVIJ-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C17H21NO3/c1-3-11-6-5-7-12-13-8-9-21-17(4-2,10-14(19)20)16(13)18-15(11)12/h5-7,18H,3-4,8-10H2,1-2H3,(H,19,20)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">2-{1,8-diethyl-1H,3H,4H,9H-pyrano[3,4-b]indol-1-yl}acetic acid</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Indoles and Derivatives</td></tr><tr><th>Subclass</th><td>Indolyl Carboxylic Acids and Derivatives</td></tr><tr><th>Direct parent</th><td>Indolyl Carboxylic Acids and Derivatives</td></tr><tr><th>Alternative parents</th><td>Indoles; Benzene and Substituted Derivatives; Pyrroles; Polyamines; Dialkyl Ethers; Carboxylic Acids; Enolates</td></tr><tr><th>Substituents</th><td>indole; benzene; pyrrole; carboxylic acid derivative; carboxylic acid; enolate; ether; dialkyl ether; polyamine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the indolyl carboxylic acids and derivatives. These are compounds containing a carboxylic acid chain (of at least 2 carbon atoms) linked to an indole ring.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For acute and long-term management of signs and symptoms of osteoarthritis and rheumatoid arthritis, as well as for the management of pain.</td></tr><tr><th>Pharmacodynamics</th><td>Etodolac is an anti-inflammatory agent with analgesic and antipyretic properties. It is used to treat osteoarthritis, rheumatoid arthritis and control acute pain. The therapeutic effects of etodolac are achieved via inhibition of the synthesis of prostaglandins involved in fever, pain, swelling and inflammation. Etodolac is administered as a racemate. As with other NSAIDs, the S-form has been shown to be active while the R-form is inactive. Both enantiomers are stable and there is no evidence of R- to S- conversion <i>in vivo</i>.</td></tr><tr><th>Mechanism of action</th><td>Similar to other NSAIDs, the anti-inflammatory effects of etodolac result from inhibition of the enzyme cycooxygenase (COX). This decreases the synthesis of peripheral prostaglandins involved in mediating inflammation. Etodolac binds to the upper portion of the COX enzyme active site and prevents its substrate, arachidonic acid, from entering the active site. Etodolac was previously thought to be a non-selective COX inhibitor, but it is now known to be 5 &#8211; 50 times more selective for COX-2 than COX-1. Antipyresis may occur by central action on the hypothalamus, resulting in peripheral dilation, increased cutaneous blood flow, and subsequent heat loss.</td></tr><tr><th>Absorption</th><td>Based on mass balance studies, the systemic bioavailability of etodolac from either the tablet or capsule formulation is at least 80%.</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>390 mL/kg</li>
</ul></td></tr><tr><th>Protein binding</th><td>&gt; 99% bound, primarily to albumin</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Etodolac is extensively metabolized in the liver. Renal elimination of etodolac and its metabolites is the primary route of excretion (72%). Metabolites found in urine (with percents of the administered dose) are: unchanged etodolac (1%), etodolac glucuronide (13%), hydroxylated metabolites (6-, 7-, and 8-OH; 5%), hydroxylated metabolite glucuronides (20%), and unidentified metabolites (33%). Fecal excretion accounts for 16% of its elimination. </p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Etodolac</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li></ul></td><td><a href="/metabolites/DBMET00148">6-Hydroxyetodolac</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/148">Details</a></td></tr><tr><td>Etodolac</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li></ul></td><td><a href="/metabolites/DBMET00149">7-Hydroxyetodolac</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/149">Details</a></td></tr><tr><td>Etodolac</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003677" target="_blank">UDP-glucuronosyltransferase 1-3</a></li>
<li><a href="/biodb/bio_entities/BE0003538" target="_blank">UDP-glucuronosyltransferase 1-9</a></li>
<li><a href="/biodb/bio_entities/BE0003678" target="_blank">UDP-glucuronosyltransferase 1-10</a></li>
<li><a href="/biodb/bio_entities/BE0003679" target="_blank">UDP-glucuronosyltransferase 2B7</a></li></ul></td><td><a href="/metabolites/DBMET00150">Etodolac acyl glucuronide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/150">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>It is not known whether etodolac is excreted in human milk; however, based on its physical-chemical properties, excretion into breast milk is expected.  Etodolac is extensively metabolized in the liver. The hydroxylated-etodolac metabolites undergo further glucuronidation followed by renal excretion and partial elimination in the feces (16% of dose). Approximately 1% of a etodolac dose is excreted unchanged in the urine with 72% of the dose excreted into urine as parent drug plus metabolite.</td></tr><tr><th>Half life</th><td>Terminal t<sub>1/2</sub>, 7.3 &#177; 4.0 hours. Distribution t<sub>1/2</sub>, 0.71 &#177; 0.50 hours</td></tr><tr><th>Clearance</th><td><ul>
	<li>Oral cl=49.1 mL/h/kg [Normal healthy adults]</li>
	<li>Oral cl=49.4 mL/h/kg [Healthy males (18-65 years)]</li>
	<li>Oral cl=35.7 mL/h/kg [Healthy females (27-65 years)]</li>
	<li>Oral cl=45.7 mL/h/kg [Eldery (&gt;65 years)]</li>
	<li>Oral cl=58.3 mL/h/kg [Renal impairement (46-73 years)]</li>
	<li>Oral cl=42.0 mL/h/kg [Hepatic impairement (34-60 years)]</li>
</ul></td></tr><tr><th>Toxicity</th><td>Selective COX-2 inhibitors have been associated with increased risk of serious cardiovascular events (e.g. myocardial infarction, stroke) in some patients. Current data is insufficient to assess the cardiovascular risk of etodolac. Etodolac may increase blood pressure and/or cause fluid retention and edema. Risk of GI toxicity including bleeding, ulceration and perforation. Risk of direct renal injury, including renal papillary necrosis. Anaphylactoid and serious skin reactions (e.g. exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis) have been reported. Common adverse events include abdominal pain, constipation, diarrhea, dyspepsia, flatulence, GI bleeding, GI perforation, nausea, peptic ulcer, vomiting, renal function abnormalities, anemia, dizziness, edema, liver function test abnormalities, headache, prolonged bleeding time, pruritus, rash, tinnitus. Symptoms of overdose include lethargy, drowsiness, nausea, vomiting, and epigastric pain.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Etodolac Action Pathway</td><td>Drug action</td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9971</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9065</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.5726</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.7462</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9242</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8988</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8178</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8545</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.7567</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.5</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9045</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.907</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9231</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9025</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8309</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.6904</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9132
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9453
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9835
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          3.4536 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9808
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.7763
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Aaipharma llc</li>
<li>Apotex inc</li>
<li>Endo pharmaceuticals inc</li>
<li>Genpharm inc</li>
<li>Ivax pharmaceuticals inc sub teva pharmaceuticals usa</li>
<li>Mylan pharmaceuticals inc</li>
<li>Sandoz inc</li>
<li>Taro pharmaceutical industries ltd</li>
<li>Teva pharmaceuticals usa inc</li>
<li>Watson laboratories inc</li>
<li>Wyeth pharmaceuticals inc</li>
<li>Point holdings inc</li>
<li>Watson laboratories inc florida</li>
<li>Actavis elizabeth llc</li>
<li>Apotex inc etobicoke site</li>
<li>Mylan laboratories inc</li>
<li>Ranbaxy laboratories ltd</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.actavis.com">Actavis Group</a></li>
<li><a href="http://www.apotex.com">Apotex Inc.</a></li>
<li>Apotheca Inc.</li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://www.atlanticbiologicals.com">Atlantic Biologicals Corporation</a></li>
<li><a href="http://www.bms.com">Bristol-Myers Squibb Co.</a></li>
<li><a href="http://bryantranchprepack.com">Bryant Ranch Prepack</a></li>
<li><a href="http://www.corepharma.com">Corepharma LLC</a></li>
<li>DHHS Program Support Center Supply Service Center</li>
<li>Direct Dispensing Inc.</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li>Eon Labs</li>
<li><a href="http://hjharkinscompanyinc.com">H.J. Harkins Co. Inc.</a></li>
<li><a href="http://www.innoviantpharmacy.com">Innoviant Pharmacy Inc.</a></li>
<li>Ivax Pharmaceuticals</li>
<li>Kaiser Foundation Hospital</li>
<li><a href="http://www.keltman.com">Keltman Pharmaceuticals Inc.</a></li>
<li>Lake Erie Medical and Surgical Supply</li>
<li><a href="http://www.letcomedical.com">Letco Medical Inc.</a></li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li>Novopharm Ltd.</li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.ohmlabs.com">Ohm Laboratories Inc.</a></li>
<li><a href="http://www.palmettopharm.com">Palmetto Pharmaceuticals Inc.</a></li>
<li><a href="http://www.parpharm.com">Par Pharmaceuticals</a></li>
<li><a href="http://www.patheon.com">Patheon Inc.</a></li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.preferredpharmaceuticals.com">Preferred Pharmaceuticals Inc.</a></li>
<li><a href="http://www.prepaksys.com">Prepak Systems Inc.</a></li>
<li><a href="http://www.prescript.net">Prescript Pharmaceuticals</a></li>
<li><a href="http://www.ranbaxy.com">Ranbaxy Laboratories</a></li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li>Redpharm Drug</li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li>Resource Optimization and Innovation LLC</li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li>St Mary's Medical Park Pharmacy</li>
<li><a href="http://statrxusa.exporterus.com">Stat Rx Usa</a></li>
<li><a href="http://www.tarousa.com">Taro Pharmaceuticals USA</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li>Torpharm Inc.</li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td>200 mg</td></tr><tr><td>Capsule</td><td>Oral</td><td>300 mg</td></tr><tr><td>Tablet</td><td>Oral</td><td>400 mg</td></tr><tr><td>Tablet</td><td>Oral</td><td>500 mg</td></tr><tr><td>Tablet, extended release</td><td>Oral</td><td>400 mg</td></tr><tr><td>Tablet, extended release</td><td>Oral</td><td>500 mg</td></tr><tr><td>Tablet, extended release</td><td>Oral</td><td>600 mg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01418">Acenocoumarol</a></td><td>The NSAID, etodolac, may increase the anticoagulant effect or acenocoumarol.</td></tr><tr><td><a href="/drugs/DB00630">Alendronate</a></td><td>Increased risk of gastric toxicity</td></tr><tr><td><a href="/drugs/DB01125">Anisindione</a></td><td>The NSAID, etodolac, may increase the anticoagulant effect of anisindione.</td></tr><tr><td><a href="/drugs/DB08822">Azilsartan medoxomil</a></td><td>Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. </td></tr><tr><td><a href="/drugs/DB00930">Colesevelam</a></td><td>Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. </td></tr><tr><td><a href="/drugs/DB00091">Cyclosporine</a></td><td>Monitor for nephrotoxicity</td></tr><tr><td><a href="/drugs/DB00266">Dicoumarol</a></td><td>The NSAID, etodolac, may increase the anticoagulant effect of dicumarol.</td></tr><tr><td><a href="/drugs/DB06210">Eltrombopag</a></td><td>Increases levels of Etodolac via metabolism decrease. UDP-glucuronosyltransferase inhibition. </td></tr><tr><td><a href="/drugs/DB01381">Ginkgo biloba</a></td><td>Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00563">Methotrexate</a></td><td>The NSAID, etodolac, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.</td></tr><tr><td><a href="/drugs/DB06813">Pralatrexate</a></td><td>NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate. </td></tr><tr><td><a href="/drugs/DB00373">Timolol</a></td><td>The NSAID, Etodolac, may antagonize the antihypertensive effect of Timolol.</td></tr><tr><td><a href="/drugs/DB00519">Trandolapril</a></td><td>The NSAID, Etodolac, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Etodolac is initiated, discontinued or dose changed.  </td></tr><tr><td><a href="/drugs/DB00374">Treprostinil</a></td><td>The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Etodolac. Monitor for increased bleeding during concomitant thearpy. </td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>The antiplatelet effects of etodolac may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid alcohol.</li>
<li>Food increases the peak plasma concentration of extended-release tablets with no effect on extent of absorption.</li>
<li>Food increases the time to peak concentration of regular release oral formulations by 1.4 to 3.8 hours with no effect on extent of absorption. </li>
<li>Take with food to reduce gastric irritation.</li></ul></td></tr></tbody></table>